Pilatus Biosciences (the “Company”), a biotechnology company focused on d shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announced that the Company will present new discovery data of its anti-PD-L1/IL10 bifunctional immunocytokine program, PLT011, at the upcoming Society for Immunotherapy of Cancer’s 38^th Annual Meeting (SITC 2023). The data will be shared in a poster presentation entitled “A novel PD-L1 antibody-IL10 fusion protein, PTL011, exhibits synergized therapeutic effect in Hepatocellular Carcinoma mouse model”, on November 4^th, 2023 (Abstract #836).

Details of the poster presentation are as follows:

Full text of the abstracts will be released on the SITC website at 8:00 a.m. ET on the same day, and the posters will be available on the Company's website.

About IL-10 and PLT011

Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor (CSIF), is a 35 kD homodimer that is composed of two non-covalently bonded monomers. IL-10 exerts multiple effects in immunoregulation and inflammation, particularly on downregulating the expression of Th1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. In contrast, IL-10 also presents several immunostimulatory properties and there have been attempts to exploit this for cancer therapy.

PLT011, a bifunctional anti-PDL1/IL10 fusion protein consisting of an anti-PD-L1 antibody with IL-10 polypeptides, was developed to dual block PD-L1/PD-1-mediated immunosuppression and enhance CD8 T-cell cytotoxicity in the tumor micro-environment. PLT011 aims to reinvigorate tumor-reactive terminally exhausted CD8+ T cells to boost anti-tumor immunity. Here, Pilatus will present the data during drug development and efficacy studies in mouse HCC model. More detailed data will be presented at SITC 2023.